Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Clear all
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis, Neuromyelitis Optica
Interventions
Not listed
Lead sponsor
Jagannadha R Avasarala
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced May 21, 2026, 7:41 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Neuromyelitis Optica
Interventions
Ravulizumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced May 21, 2026, 7:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Interventions
Inebilizumab, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced May 21, 2026, 7:41 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
B-cell Mediated Autoimmune Disorders
Interventions
Azercabtagene zapreleucel (azer-cel)
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 7:41 PM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder, NMOSD
Interventions
Satralizumab 120 mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced May 21, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced May 21, 2026, 7:41 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 71 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 7:41 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
Inebilizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
La Jolla, California • Loma Linda, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 21, 2026, 7:41 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Multiple Sclerosis, Neuromyelitis Optica, Demyelinating Autoimmune Diseases, CNS
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced May 21, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced May 21, 2026, 7:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced May 21, 2026, 7:41 PM EDT
Enrolling by invitation Not applicable Interventional
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
MR-C-014
Device
Lead sponsor
MedRhythms, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 21, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
20
States / cities
Aurora, Colorado • Miami, Florida • Vero Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced May 21, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
NMO Spectrum Disorder
Interventions
Acceptance and Commitment Therapy
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced May 21, 2026, 7:41 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced May 21, 2026, 7:41 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Interventions
Ultomiris
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 21, 2026, 7:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2041
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced May 21, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo, Baseline Treatment
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 74 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced May 21, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ublituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced May 21, 2026, 7:41 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced May 21, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Bevacizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced May 21, 2026, 7:41 PM EDT
Terminated Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
San Francisco, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced May 21, 2026, 7:41 PM EDT
Not yet recruiting Phase 4 Interventional
View directory record Official record
Conditions
NMOSD
Interventions
Rituximab (R), Eculizumab (Soliris®), Ravulizumab, Satralizumab, Inebilizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 21, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF), oral corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Miami, Florida • Columbus, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced May 21, 2026, 7:41 PM EDT